Amgen (AMGN) Cost of Revenue (2009 - 2026)

Amgen (AMGN) has reported Cost of Revenue for 18 consecutive years, with $2.7 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Cost of Revenue fell 7.55% year-over-year to $2.7 billion; the TTM figure through Mar 2026 stood at -$1.8 billion (down 119.67% YoY), while the FY2025 annual figure was $1.3 billion, down 89.8% from the prior year.
• Cost of Revenue came in at $2.7 billion for Q1 2026 at Amgen, up from -$7.7 billion in the prior quarter.
• The five-year high for Cost of Revenue was $3.2 billion in Q2 2024, with the low at -$7.7 billion in Q4 2025.
• Average Cost of Revenue over 5 years is $1.3 billion, with a median of $1.7 billion recorded in 2022.
• The largest YoY upside for Cost of Revenue was 4240.85% in 2025 against a maximum downside of 349.0% in 2025.
• Year by year, Cost of Revenue stood at $1.7 billion in 2022, then jumped by 78.13% to $3.1 billion in 2023, then changed by 0.0% to $3.1 billion in 2024, then slumped by 349.0% to -$7.7 billion in 2025, then jumped by 135.41% to $2.7 billion in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $2.7 billion, -$7.7 billion, and $3.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.